Targeted therapy of ovarian cancer including immune check point inhibitor
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects. Some anti-angiogenic agents, poly(ADP-ribose) polymerase, and immune checkpoint inhibitors have shown efficacy in early stages of development for the treatment of epithelial ovarian cancer. As demonstrated in recent clinical trials, the use of bevacizumab, cediranib, pazopanib, olaparib, and rucaparib, either alone or in combination with conventional cytotoxic agents, improves progression-free survival. Trials on immune checkpoint inhibitors such as nivolumab have revealed prolonged responses in a small set of ovarian cancer cases but require further exploration. In this review, we discuss the role of targeted therapies against ovarian cancer, including the use of immune checkpoint inhibitors.
Abstract
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects. Some anti-angiogenic agents, poly(ADP-ribose) polymerase, and immune checkpoint inhibitors have shown efficacy in early stages of development for the treatment of epithelial ovarian cancer. As demonstrated in recent clinical trials, the use of bevacizumab, cediranib, pazopanib, olaparib, and rucaparib, either alone or in combination with conventional cytotoxic agents, improves progression-free survival. Trials on immune checkpoint inhibitors such as nivolumab have revealed prolonged responses in a small set of ovarian cancer cases but require further exploration. In this review, we discuss the role of targeted therapies against ovarian cancer, including the use of immune checkpoint inhibitors.
참고문헌 (40)
- "Percentage of deaths from 10 cancer deaths among men in 2015" (2012)[URL]
- Heintz AP, "Carcinoma of the ovary: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer", Int J Gynaecol Obstet, 95(Suppl 1), pp.S161~S192 (2006)
- Monk BJ, "Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer:from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds", Int J Gynecol Cancer, 19(Suppl 2), pp.S63~S67 (2009)
- Bookman MA, "Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup", J Clin Oncol, 27, pp.1419~1425 (2009)
- du Bois A, "Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens", J Clin Oncol, 24, pp.1127~1135 (2006)
- Pfisterer J, "Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO", J Natl Cancer Inst, 98, pp.1036~1045 (2006)
- Hoskins P, "Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel", J Natl Cancer Inst, 102, pp.1547~1556 (2010)
- Armstrong DK, "Intraperitoneal cisplatin and paclitaxel in ovarian cancer", N Engl J Med, 354, pp.34~43 (2006)
- Meehan RS, "New treatment option for ovarian cancer: PARP inhibitors", Gynecol Oncol Res Pract, 3, pp.3~ (2016)
- Colombo N, "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21(Suppl 5), pp.v23~v30 (2010)
- Katsumata N, "Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial", Lancet, 374, pp.1331~1338 (2009)
- Katsumata N, "Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial", Lancet Oncol, 14, pp.1020~1026 (2013)
- Pignata S, "Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial", Lancet Oncol, 15, pp.396~405 (2014)
- Chan JK, "Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer", N Engl J Med, 374, pp.738~748 (2016)
- Rustin GJ, "Early versus delayed treatment of relapsed ovarian cancer (MRC OV05", EORTC 55955): a randomised trial, 2010, pp.376, 1155~1163
- "Ovarian cancer" (2017)[URL]
- Markman M, "Second-line treatment of ovarian cancer", Oncologist, 5, pp.26~35 (2000)
- Markman M, "Second-line platinum therapy in patients with ovarian cancer previously treated with cis", J Clin Oncol, 9, pp.389~393 (1991)
- Lokadasan R, "Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments", Ecancermedicalscience, 10, pp.626~ (2016)
- Abu-Jawdeh GM, "Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms", Lab Invest, 74, pp.1105~1115 (1996)
- Burger RA, "Incorporation of bevacizumab in the primary treatment of ovarian cancer", N Engl J Med, 365, pp.2473~2483 (2011)
- Perren TJ, "A phase 3 trial of bevacizumab in ovarian cancer", N Engl J Med, 365, pp.2484~2496 (2011)
- Oza AM, "Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial", Lancet Oncol, 16, pp.928~936 (2015)
- Aghajanian C, "OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer", J Clin Oncol, 30, pp.2039~2045 (2012)
- Pujade-Lauraine E, "Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial", J Clin Oncol, 32, pp.1302~1308 (2014)
- Stockler MR, "Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer", J Clin Oncol, 32, pp.1309~1316 (2014)
- Aghajanian C, "Updated overall survival analysis in OCEANS, a randomized phase III trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV)or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC)", Proceedings of the 37th Congress of the European Society for Medical Oncology, pp.319~ (2012), Oxford University Press
- Pujade-Lauraine E, "AURELIA: a randomized phase III trial evaluating bevacizumab (BEV)plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)", J Clin Oncol, 30(18 Suppl), pp.327s~ (2012)
- Witteveen P, "Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)", Eur J Cancer, 49(Suppl 3), pp.S3~ (2013)
- Friedlander M, "A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer", Gynecol Oncol, 119, pp.32~37 (2010)
- du Bois A, "Incorporation of pazopanib in maintenance therapy of ovarian cancer", J Clin Oncol, 32, pp.3374~3382 (2014)
- Matulonis UA, "Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer", J Clin Oncol, 27, pp.5601~5606 (2009)
- Raja FA, "Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer", Br J Cancer, 105, pp.884~889 (2011)
- Lord CJ, "Mechanisms of resistance to therapies targeting BRCA-mutant cancers", Nat Med, 19, pp.1381~1388 (2013)
- Ledermann J, "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer", N Engl J Med, 366, pp.1382~1392 (2012)
- Ledermann J, "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial", Lancet Oncol, 15, pp.852~861 (2014)
- McNeish IA, "Results of ARIEL2:a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis", J Clin Oncol, 33(15 Suppl), pp.5508~ (2015)
- Liu JF, "Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study", Lancet Oncol, 15, pp.1207~1214 (2014)
- Hodi FS, "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients", Proc Natl Acad Sci U S A, 100, pp.4712~4717 (2003)
- Hamanishi J, "Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer", J Clin Oncol, 32(15 Suppl), pp.5511~ (2014)